ChadTuberculosis profile
Population  2014 14 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.1 (2.2–4.1) 23 (16–30)
Mortality (HIV+TB only) 2.1 (1.4–3) 15 (10–22)
Prevalence  (includes HIV+TB) 28 (16–45) 209 (115–331)
Incidence  (includes HIV+TB) 22 (19–24) 159 (141–179)
Incidence (HIV+TB only) 6 (4.7–7.4) 44 (35–55)
         
Case detection, all forms (%) 55 (49–62)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.3–3.1) 17 (4.4–30)
MDR-TB cases among notified pulmonary
TB cases
170 (30–310) 140 (36–250)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 5 724   493
Pulmonary, clinically diagnosed 4 257   0
Extrapulmonary 1 499   0
       
Total new and relapse 11 973    
Previously treated, excluding relapses 332    
Total cases notified 12 305    
Among 11 973 new and relapse cases:
981 (8%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 217 (26%) 217
Laboratory-confirmed RR-/MDR-TB cases     22
Patients started on MDR-TB treatment ***     12
TB/HIV 2014 Number (%)
TB patients with known HIV status 6 636 (54)
HIV-positive TB patients 1 291 (19)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 721 (56)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (74) 9 127
Previously treated cases registered in 2013 (53) 722
HIV-positive TB cases, all types, registered in 2013   0
RR-/MDR-TB cases started on second-line treatment in 2012   0
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 0.6
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? No
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-24 Data: www.who.int/tb/data